{"entity":{"id":"shionogi","kind":"company","name":"Shionogi","aka":["Shionogi & Co., Ltd.","塩野義製薬","TSE:4507"],"tldr":"Shionogi is a long-established Osaka pharmaceutical company, best known for antibiotics and antivirals, that developed the platinum chemotherapy nedaplatin sold in Japan as Aqupla.","summary":"Shionogi, founded in Osaka in 1878, is a research-based pharmaceutical company with strengths in infectious disease, including the antiviral Xofluza and the antibiotic cefiderocol, and in pain and central nervous system medicines. In oncology it developed nedaplatin (254-S), a second-generation platinum agent with less kidney toxicity than cisplatin, approved in Japan in 1995 as Aqupla for head and neck, lung, oesophageal, bladder, cervical, ovarian and testicular cancers.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.shionogi.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["nedaplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Osaka","country":"JP","companyType":"pharma","website":"https://www.shionogi.com/","ticker":"TSE:4507","founded":1878,"stage":"public","investors":[],"funding":[]},"route":"/companies/shionogi/","neighbours":{"drug":[{"id":"nedaplatin","kind":"drug","name":"Nedaplatin","route":"/drugs/nedaplatin/"}]}}